Skip to main content
Premium Trial:

Request an Annual Quote

Public Comment Phase on Warfarin Genetic Test Reimbursement Ends Tomorrow

NEW YORK (GenomeWeb News) – The Center for Medicare and Medicaid Services will stop taking public comments tomorrow, Sept. 3, about whether Medicare should provide reimbursement for DNA tests for the common anticoagulant warfarin.
 
Tomorrow marks the end of a public comment phase begun a month ago as part of a CMS National Coverage Analysis investigation to determine whether there is sufficient evidence that a pharmacogenomic test for warfarin is effective enough for coverage.
 
The US Food and Drug Administration updated the label for warfarin in 2007 to state that people with variations of the genes CYP2C9 and VKORC1 may respond to warfarin differently than patients without those variations.
 
FDA Deputy Commissioner Janet Woodcock said at the time that the administration was not directing doctors to use genetic tests, and that the agency intended it as “informational” to doctors about the variability of drug response.
 
Public comments about the CMS review are available here.
 

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.